Exabis Library
Welcome to the e-CCO Library!
DOP025: Efficacy of vedolizumab on extraintestinal manifestation in patients with inflammatory bowel disease: a post-hoc analysis of the OBSERV-IBD cohort from the GETAID
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
DOP025: Efficacy of vedolizumab on extraintestinal manifestation in patients with Inflammatory Bowel Disease: A post-hoc analysis of the OBSERV-IBD cohort from the GETAID
2017
ECCO'17 Barcelona
1
DOP025: Tofacitinib for the treatment of ulcerative colitis: analysis of malignancy rates from the OCTAVE clinical programme
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
DOP025: Tofacitinib for the treatment of Ulcerative Colitis: Analysis of malignancy rates from the OCTAVE clinical programme
2018
ECCO'18 Vienna
Tuesday, 8 May 2018, 11:36 AM
1
DOP026: Efficacy and safety of dose escalation to tofacitinib 10 mg BID for patients with ulcerative colitis following loss of response on tofacitinib 5 mg BID maintenance therapy: results from OCTAVE open
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
DOP026: Efficacy and safety of dose escalation to tofacitinib 10 mg BID for patients with Ulcerative Colitis following loss of response on tofacitinib 5 mg BID maintenance therapy: Results from OCTAVE open
2018
ECCO'18 Vienna
Tuesday, 8 May 2018, 11:36 AM
1
DOP026: Sustained remission with vedolizumab in patients with moderately to severely active ulcerative colitis: a GEMINI 1 post hoc analysis of week 14 remitters
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
DOP026: Sustained remission with vedolizumab in patients with Moderately to Severely active Ulcerative Colitis: A GEMINI 1 post hoc analysis of Week 14 remitters
2017
ECCO'17 Barcelona
1
DOP026: The Toll-like-receptor 9 agonist DIMS0150 demonstrates therapeutic efficacy for the patient-reported outcome measures PRO-2 and ClinPRO in moderate-to-severe active ulcerative colitis
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
DOP027: Efficacy and safety of an additional 8 weeks of tofacitinib induction therapy: Results of the OCTAVE open study for tofacitinib 8-week induction non-responders
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
DOP027: Efficacy and safety of an additional eight weeks of tofacitinib induction therapy: Results of the OCTAVE open study for tofacitinib eigth-week induction non-responders
2018
ECCO'18 Vienna
Tuesday, 8 May 2018, 11:36 AM
1
DOP027: Large scale drug screen reveals benzimidazole anti-helminthics as potential anti-TNF co-therapy
2016
ECCO'16 DOP
1
DOP027: Large-scale drug screen reveals benzimidazole anti-helminthics as potential anti-TNF co-therapy
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
DOP027: Long-term efficacy and safety of ustekinumab in refractory Crohn's disease patients: a multicenter retrospective experience
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
DOP027: Long-term efficacy and safety of ustekinumab in refractory Crohn’s Disease patients: A multicenter retrospective experience
2017
ECCO'17 Barcelona
1
DOP028: 2nd N-ECCO consensus statements on the European nursing roles in caring for patients with Crohn’s Disease or Ulcerative Colitis
2018
ECCO'18 Vienna
Tuesday, 8 May 2018, 11:36 AM
1
DOP028: Antibodies towards vedolizumab appear from week 2 onwards and disappear upon treatment
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
DOP028: Antibodies towards vedolizumab appear from week 2 onwards and disappear upon treatment
2017
ECCO'17 Barcelona
1
DOP028: Efficacy and safety of biosimilar infliximab after one year: results from a prospective nationwide cohort
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
DOP028: Efficacy and safety of biosimilar infliximab after one-year: results from a prospective nationwide cohort
2016
ECCO'16 DOP
1